EXPLORATORY BASKET TRIAL OF CABOZANTINIB PLUS ATezolizumab IN ADVANCED AND PROGRESSIVE NEOPLASMS OF THE ENDOCRINE SYSTEM (CABATEN STUDY)

**Primary endpoint:** Overall Objective Response Rate (ORR)

**Estimated Primary Completion Date:** 3Q 2021 (S1), 2023 (S2)

**Cohort 1:** Well-differentiated neuroendocrine tumors of lung origin (WHO grade 1 and 2, typical and atypical carcinoids)  
N = 9 + 15 pts

**Cohort 2:** Anaplastic thyroid cancer  
N = 9 + 15 pts

**Cohort 3:** Adrenocortical carcinoma  
N = 9 + 15 pts

**Cohort 4:** Pheochromocytoma and paraganglioma  
N = 9 + 15 pts

**Cohort 5:** Well-differentiated neuroendocrine tumors of gastroenteropancreatic (WHO grade 1 and 2)  
N = 9 + 15 pts

**Cohort 6:** Poorly differentiated neuroendocrine tumors (WHO grade 3), excluding small cell lung cancer  
N = 9 + 15 pts

**Cabozantinib 40 mg PO + Atezolizumab 1200 mg Q3W**

**PIs:** Dr. Jaume Capdevila | Dr. Enrique Grande